| Literature DB >> 36170685 |
Yuge Zhou1, Ning Tian2, Peiling Li1, Yanting He1, Lijun Tong2, Weining Xie3,4.
Abstract
OBJECTIVE: The aim of this study is to investigate the correlation between neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) with nonalcoholic fatty liver disease (NAFLD).Entities:
Mesh:
Year: 2022 PMID: 36170685 PMCID: PMC9521580 DOI: 10.1097/MEG.0000000000002439
Source DB: PubMed Journal: Eur J Gastroenterol Hepatol ISSN: 0954-691X Impact factor: 2.586
Fig. 1.Flow chart of participant selection.
Baseline characteristics of participants
| Variable | Non-NAFLD | NAFLD | |
|---|---|---|---|
| N | 3413 | 1085 | - |
| Age (years) | 39.56 ± 12.31 | 44.76 ± 11.64 | <0.001 |
| Gender (male, %) | 1482 (43.42%) | 809 (74.56%) | <0.001 |
| BMI (kg/m2) | 23.11 ± 2.16 | 24.70 ± 2.30 | <0.001 |
| ALT (U/L) | 21.20 ± 15.79 | 33.69 ± 21.78 | <0.001 |
| AST (U/L) | 19.91 ± 9.86 | 22.68 ± 9.25 | <0.001 |
| γ-GT (U/L) | 25.75 ± 25.71 | 45.05 ± 36.99 | <0.001 |
| TG (mmol/L) | 1.25 ± 0.79 | 2.20 ± 1.54 | <0.001 |
| TC (mmol/L) | 5.45 ± 1.02 | 5.90 ± 1.11 | <0.001 |
| HDL (mmol/L) | 1.58 ± 0.28 | 1.41 ± 0.24 | <0.001 |
| LDL (mmol/L) | 3.10 ± 0.72 | 3.48 ± 0.82 | <0.001 |
| UA (μmol/L) | 337.12 ± 88.99 | 418.03 ± 101.86 | <0.001 |
| GLU (mmol/L) | 5.08 ± 0.50 | 5.45 ± 0.73 | <0.001 |
| NE (×109/L) | 3.62 ± 1.19 | 3.99 ± 1.20 | <0.001 |
| PLT (×109/L) | 245.80 ± 52.76 | 247.34 ± 51.63 | 0.399 |
| LYM (×109/L) | 2.22 ± 0.59 | 2.46 ± 0.68 | <0.001 |
| NLR | 1.72 ± 0.69 | 1.71 ± 0.63 | 0.761 |
| PLR | 74.00 ± 26.47 | 66.20 ± 20.82 | <0.001 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GLU, glucose; γ-GT, γ-glutamyl transpeptidase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LYM, lymphocyte; NAFLD, nonalcoholic fatty liver disease; NE, neutrophilic granulocyte; NLR, neutrophil-to-lymphocyte ratio; PLT, platelet; PLR, platelet-to-lymphocyte ratio; TG, triglyceride; TC, total cholesterol; UA, uric acid.
Correlations between exposure factors and nonalcoholic fatty liver disease
| Exposure | Statistic | OR (95% CI) | |
|---|---|---|---|
| Age (years) | 40.81 ± 12.35 | 1.03 (1.03, 1.04) | <0.001 |
| Gender | <0.001 | ||
| Male | 2291 (50.93%) | 1 | |
| Female | 2207 (49.07%) | 0.26 (0.23, 0.31) | |
| BMI (kg/m2) | 23.50 ± 2.29 | 1.51 (1.44, 1.58) | <0.001 |
| ALT (U/L) | 24.22 ± 18.22 | 1.06 (1.05, 1.07) | <0.001 |
| AST (U/L) | 20.58 ± 9.78 | 0.94 (0.93, 0.96) | <0.001 |
| γ-GT (U/L) | 30.40 ± 29.99 | 1.03 (1.03, 1.03) | <0.001 |
| TG (mmol/L) | 1.48 ± 1.10 | 2.86 (2.60, 3.14) | <0.001 |
| TC (mmol/L) | 5.56 ± 1.06 | 1.48 (1.38, 1.57) | <0.001 |
| HDL (mmol/L) | 1.54 ± 0.28 | 0.07 (0.05, 0.09) | <0.001 |
| LDL (mmol/L) | 3.19 ± 0.77 | 1.90 (1.74, 2.09) | <0.001 |
| UA (μmol/L) | 356.63 ± 98.53 | 1.01 (1.09, 1.01) | <0.001 |
| GLU (mmol/L) | 5.17 ± 0.58 | 2.88 (2.54, 3.27) | <0.001 |
| NE (×109/L) | 3.71 ± 1.20 | 1.28 (1.21, 1.35) | <0.001 |
| PLT (×109/L) | 246.17 ± 52.49 | 1.00 (0.10, 1.00) | 0.391 |
| LYM (×109/L) | 2.27 ± 0.62 | 1.83 (1.64, 2.04) | <0.001 |
| NLR | 1.72 ± 0.67 | 0.99 (0.89, 1.09) | 0.764 |
| PLR | 72.12 ± 25.44 | 0.99 (0.98, 0.99) | <0.001 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; GLU, glucose; γ-GT, γ-glutamyl transpeptidase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LYM, lymphocyte; NAFLD, nonalcoholic fatty liver disease; NE, neutrophilic granulocyte; NLR, neutrophil-to-lymphocyte ratio; OR, odds ratio; PLT, platelet; PLR, platelet-to-lymphocyte ratio; TG, triglyceride; TC, total cholesterol; UA, uric acid.
Relationship between neutrophil-to-lymphocyte ratio and nonalcoholic fatty liver disease in different models
| Variable | Model 1 | Model 2 | Model 3 | |||
|---|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | OR (95% CI) | ||||
| NLR | 0.99 (0.89, 1.09) | 0.764 | 0.99 (0.89, 1.10) | 0.839 | 0.93 (0.82, 1.06) | 0.305 |
| NLR (trisection) | ||||||
| <1.40 | 1 | 1 | 1 | 1 | ||
| 1.4~1.84 | 0.92 (0.78, 1.09) | 0.341 | 0.92 (0.77, 1.10) | 0.351 | 1.02 (0.83, 1.26) | 0.840 |
| >1.84 | 0.99 (0.84, 1.17) | 0.915 | 1.04 (0.87, 1.23) | 0.703 | 1.10 (0.90, 1.35) | 0.368 |
Model 1 was adjusted for: none.
Model 2 was adjusted for: gender, age.
Model 3 was adjusted for: gender, age, BMI, ALT, AST, γ-GT, TG, TC, HDL, LDL, UA, GLU, NE, PLT, LYM, and PLR.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; GLU, glucose; γ-GT, γ-glutamyl transpeptidase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LYM, lymphocyte; NAFLD, nonalcoholic fatty liver disease; NE, neutrophilic granulocyte; NLR, neutrophil-to-lymphocyte ratio; OR, odds ratio; PLT, platelet; PLR, platelet-to-lymphocyte ratio; TG, triglyceride; TC, total cholesterol; UA, uric acid.
Relationship between platelet-to-lymphocyte ratio and nonalcoholic fatty liver disease in different models
| Variable | Model 1 | Model 2 | Model 3 | |||
|---|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | OR (95% CI) | ||||
| PLR | 0.99 (0.98, 0.99) | <0.001 | 0.99 (0.99, 0.10) | <0.001 | 0.10 (0.10, 1.00) | 0.445 |
| PLR (trisection) | ||||||
| <59.54 | 1 | 1 | 1 | 1 | ||
| 59.54~77.65 | 1.95 (1.64, 2.32) | <0.001 | 1.37 (1.14, 1.65) | 0.001 | 0.99 (0.79, 1.23) | 0.903 |
| >77.65 | 1.65 (1.39, 1.97) | <0.001 | 1.35 (1.12, 1.62) | 0.002 | 1.10 (0.89, 1.37) | 0.365 |
Model 1 was adjusted for: none.
Model 2 was adjusted for: gender, age.
Model 3 was adjusted for: gender, age, BMI, ALT, AST, γ-GT, TG, TC, HDL, LDL, UA, GLU, NE, PLT, LYM and NLR.
Fig. 2.The relationship between NLR and NAFLD by smooth curve fitting. By two-piecewise linear regression model, the inflection point of NLR was 1.23. On the left side of the inflection point (NLR < 1.23), a positive correlation was detected between NLR and NAFLD. However, no significant correlation between NLR and NAFLD on the right of inflection point was observed. NAFLD, nonalcoholic fatty liver disease; NLR, neutrophil-to-lymphocyte ratio.
Fig. 3.The relationship between PLR and NAFLD by smooth curve fitting. By two-piecewise linear regression model, the inflection point of PLR was 42.29. PLR was found to be negatively associated with NAFLD on the right side of the inflection point (PLR ≧ 42.29). However, the association between PLR and NAFLD on the left of inflection point was not detected. NAFLD, nonalcoholic fatty liver disease; PLR, platelet-to-lymphocyte ratio.
The independent correlation between neutrophil-to-lymphocyte ratio and nonalcoholic fatty liver disease by multivariate piecewise linear regression
| Infection point of NLR | Effect size (β) | 95% CI | ||
|---|---|---|---|---|
| Lower | Upper | |||
| <1.23 | 2.35 | 1.20 | 4.61 | 0.013 |
| ≧1.23 | 0.91 | 0.80 | 1.03 | 0.118 |
Adjusting for gender, age, BMI, ALT, AST, γ-GT, TG, TC, HDL, LDL, UA, GLU, NE, PLT, LYM and PLR.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; GLU, glucose; γ-GT, γ-glutamyl transpeptidase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LYM, lymphocyte; NAFLD, nonalcoholic fatty liver disease; NE, neutrophilic granulocyte; NLR, neutrophil-to-lymphocyte ratio; OR, odds ratio; PLT, platelet; PLR, platelet-to-lymphocyte ratio; TG, triglyceride; TC, total cholesterol; UA, uric acid.
The independent correlation between platelet-to-lymphocyte ratio and nonalcoholic fatty liver disease by multivariate piecewise linear regression
| Infection point of PLR | Effect size (β) | 95% CI | ||
|---|---|---|---|---|
| Lower | Upper | |||
| <42.29 | 1.02 | 0.99 | 1.06 | 0.183 |
| ≧42.29 | 0.99 | 0.98 | 0.99 | <0.001 |
Adjusting for gender, age, BMI, ALT, AST, γ-GT, TG, TC, HDL, LDL, UA, GLU, NE, PLT, LYM and NLR.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; GLU, glucose; γ-GT, γ-glutamyl transpeptidase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LYM, lymphocyte; NAFLD, nonalcoholic fatty liver disease; NE, neutrophilic granulocyte; NLR, neutrophil-to-lymphocyte ratio; OR, odds ratio; PLT, platelet; PLR, platelet-to-lymphocyte ratio; TG, triglyceride; TC, total cholesterol; UA, uric acid.